Vantage Biosciences

Vantage Biosciences is a UK-based clinical stage biotechnology company targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye. Our mission is to enable patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.